4/A: ResMed Director Jan De Witte Amends Filing to Disclose Rule 10b5-1 Trading Plan
SEC Filing
ResMed director Jan De Witte amended a previous SEC filing to indicate a stock sale was executed under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Jan De Witte, a director of ResMed Inc., filed an amendment to a Form 4, originally filed on May 17, 2024, to report a transaction made on May 15, 2024.
- The amendment clarifies that the sale of 360 shares of ResMed common stock at a price of $218.29 per share was conducted under a Rule 10b5-1 trading plan adopted on February 2, 2024.
- Following the transaction, De Witte directly owns 7,519 shares of ResMed common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to insider trading. It doesn't contain information that would significantly impact investor sentiment positively or negatively.
Industry Context
The filing relates to insider trading activity, which is a common occurrence in publicly traded companies. Rule 10b5-1 plans are frequently used by corporate insiders to sell shares while avoiding accusations of trading on non-public information.
Key Dates
| Date | Description |
|---|---|
| 02/02/2024 | Date Rule 10b5-1 plan was adopted |
| 05/15/2024 | Date of stock sale transaction |
| 05/17/2024 | Date of original Form 4 filing |
| 05/22/2024 | Date of amended Form 4/A filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.